SuperworthuniQure EV/EBIT QURE
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 2.6×
- Aug 2022
- Peer median
- 9.0×
uniQure has no meaningful EV/EBIT today: it made an operating loss of $200.1M over the last twelve months.
It was last meaningful in Aug 2022, at 2.6×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2022 | 2.6× | 0.7× | 2.6× |
| 2021 | 1.5× | 1.5× | 3.7× |
Against its peers
Companies in Drug Manufacturers - General nearest uniQure's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| QUREuniQure | n/m |
| PAHCPhibro Animal Health | 11.7× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 7.6× |
| ANIPANI Pharmaceuticals | 10.5× |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | 6.9× |
| AMPHAmphastar Pharmaceuticals | 12.2× |
| PBHPrestige Consumer Healthcare | 14.5× |
| NRIXNurix Therapeutics | 7.1× |
| ABUSArbutus Biopharma | 4.9× |
| Peer median | 9.0× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on uniQure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.